Log in
NASDAQ:BBIO

BridgeBio Pharma Stock Forecast, Price & News

$48.47
+1.49 (+3.17 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$46.90
Now: $48.47
$48.64
50-Day Range
$38.38
MA: $40.98
$48.47
52-Week Range
$14.23
Now: $48.47
$48.64
Volume535,221 shs
Average Volume732,610 shs
Market Capitalization$5.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.34
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; and collaboration with Salk Institute for Biological Studies. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BBIO
CUSIPN/A
CIKN/A
Phone650-391-9740
Employees248

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.56 million
Book Value$1.76 per share

Profitability

Net Income$-260,590,000.00

Miscellaneous

Market Cap$5.94 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableNot Optionable
$48.47
+1.49 (+3.17 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BridgeBio Pharma (NASDAQ:BBIO) Frequently Asked Questions

How has BridgeBio Pharma's stock price been impacted by COVID-19?

BridgeBio Pharma's stock was trading at $23.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BBIO shares have increased by 103.0% and is now trading at $48.47.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BridgeBio Pharma?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BridgeBio Pharma
.

What stocks does MarketBeat like better than BridgeBio Pharma?

Wall Street analysts have given BridgeBio Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BridgeBio Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BridgeBio Pharma's next earnings date?

BridgeBio Pharma is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for BridgeBio Pharma
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.98) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.08. The firm had revenue of $8.13 million for the quarter, compared to analysts' expectations of $17.25 million.
View BridgeBio Pharma's earnings history
.

What price target have analysts set for BBIO?

9 analysts have issued 12-month price targets for BridgeBio Pharma's stock. Their forecasts range from $38.00 to $60.00. On average, they anticipate BridgeBio Pharma's stock price to reach $47.40 in the next twelve months. This suggests that the stock has a possible downside of 2.2%.
View analysts' price targets for BridgeBio Pharma
.

Who are some of BridgeBio Pharma's key competitors?

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Square (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

Who are BridgeBio Pharma's key executives?

BridgeBio Pharma's management team includes the following people:
  • Dr. Neil Kumar, Co-Founder, CEO & Director (Age 41, Pay $897.57k)
  • Dr. Charles J. Homcy, Chairman of Pharmaceuticals & Lead Director (Age 72, Pay $735.54k)
  • Dr. Richard H. Scheller, Chairman of R&D and Director (Age 67)
  • Dr. Brian C. Stephenson, Chief Financial Officer (Age 39)
  • Ms. Yi Ching Yau, Chief Accounting Officer
  • Dr. Uma Sinha, Chief Scientific Officer (Age 63)
  • Dr. Cameron Turtle Ph.D., Sr. VP of Portfolio Management & Corp. Devel. (Age 30)
  • Dr. Michael Thomas Henderson M.D., Chief Bus. Officer (Age 30)
  • Mr. Eli M. Wallace, Chief Scientific Officer of Residence - Oncology Programs (Age 53)
  • Dr. Thomas Trimarchi, Sr. VP of Product

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.00%), American International Group Inc. (4.59%), State Street Corp (1.92%), JPMorgan Chase & Co. (1.06%), Lord Abbett & CO. LLC (0.50%) and Charles Schwab Investment Management Inc. (0.43%). Company insiders that own BridgeBio Pharma stock include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Frank Mccormick, Genetic Disorder LP Kkr, Global Investors Lp Viking, Michael Thomas Henderson and Neil Kumar.
View institutional ownership trends for BridgeBio Pharma
.

Which major investors are selling BridgeBio Pharma stock?

BBIO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Lord Abbett & CO. LLC, Victory Capital Management Inc., AQR Capital Management LLC, Morgan Stanley, Jane Street Group LLC, Massachusetts Financial Services Co. MA, and Trexquant Investment LP. Company insiders that have sold BridgeBio Pharma company stock in the last year include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Frank Mccormick, Genetic Disorder LP Kkr, Michael Thomas Henderson, and Neil Kumar.
View insider buying and selling activity for BridgeBio Pharma
.

Which major investors are buying BridgeBio Pharma stock?

BBIO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Charles Schwab Investment Management Inc., Voloridge Investment Management LLC, GSA Capital Partners LLP, DekaBank Deutsche Girozentrale, Cubist Systematic Strategies LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have bought BridgeBio Pharma stock in the last two years include Brian C Stephenson, Genetic Disorder LP Kkr, Global Investors Lp Viking, and Michael Thomas Henderson.
View insider buying and selling activity for BridgeBio Pharma
.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $48.47.

How big of a company is BridgeBio Pharma?

BridgeBio Pharma has a market capitalization of $5.94 billion and generates $40.56 million in revenue each year. The company earns $-260,590,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. BridgeBio Pharma employs 248 workers across the globe.

What is BridgeBio Pharma's official website?

The official website for BridgeBio Pharma is bridgebio.com.

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The company can be reached via phone at 650-391-9740.

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.